Login / Signup

Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease.

Espen Thiis-EvensenAmalie Christine PooleHong-Thien Thi NguyenJon Sponheim
Published in: BMC cancer (2020)
We found no treatment benefit with regard to TTP for our patients that experienced OR compared to those who achieved SD.
Keyphrases
  • end stage renal disease
  • neuroendocrine tumors
  • chronic kidney disease
  • ejection fraction
  • newly diagnosed
  • squamous cell carcinoma
  • peritoneal dialysis
  • combination therapy
  • liver metastases